Dose Conversion from Indapamide to Chlorthalidone
When switching from indapamide to chlorthalidone for hypertension, use a 1:5 dose ratio: indapamide 1.25 mg converts to chlorthalidone 12.5 mg, and indapamide 2.5 mg converts to chlorthalidone 25 mg, with the switch made directly without titration or washout period.
Conversion Dosing
Based on FDA labeling and comparative pharmacology:
- Indapamide 1.25 mg → Chlorthalidone 12.5 mg daily 1, 2
- Indapamide 2.5 mg → Chlorthalidone 25 mg daily 1, 2
The conversion is straightforward because both drugs demonstrate maximal blood pressure-lowering effects at these standard doses. Research confirms that indapamide 1.25-2.5 mg and chlorthalidone 12.5-25 mg produce similar blood pressure reductions of approximately 9/4 mmHg compared to placebo 3.
Rationale for Direct Conversion
Make the switch immediately without dose titration or washout. Both indapamide and chlorthalidone are thiazide-like diuretics with similar mechanisms of action at the distal tubule 4. Meta-analyses demonstrate that indapamide and chlorthalidone have comparable antihypertensive potency, both superior to hydrochlorothiazide by approximately 5 mmHg systolic 5. The 2025 AHA/ACC guidelines specifically recommend chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg as preferred thiazide-like diuretics for resistant hypertension 6.
Critical Monitoring Parameters
Week 1-2 Post-Switch:
- Serum potassium - Chlorthalidone causes more potassium loss than indapamide 7
- Blood pressure - Check at 1-2 weeks to ensure maintained control
- Serum sodium - Chlorthalidone has slower hyponatremia correction rates 7
Week 4 Post-Switch:
- Complete metabolic panel including potassium, sodium, creatinine, glucose, uric acid
- Blood pressure reassessment - Both drugs reach steady-state effects by 4 weeks 2, 1
Ongoing Monitoring:
- Chlorthalidone has a longer half-life (40-60 hours) compared to indapamide (14-18 hours), meaning effects persist longer and adverse metabolic effects may be more pronounced 4
Key Clinical Pitfalls
Hypokalemia risk is higher with chlorthalidone. Studies show chlorthalidone causes more potassium depletion than other thiazides 7. Consider:
- Baseline potassium <4.0 mEq/L: Add potassium supplementation or potassium-sparing agent prophylactically
- Patients on ACE inhibitors/ARBs: Lower hypokalemia risk but still monitor
- Patients on digoxin: Hypokalemia increases toxicity risk - monitor closely
Hyponatremia develops more slowly with chlorthalidone but corrects more slowly. The longer half-life means sodium disturbances take longer to manifest and resolve 7. Elderly patients (>65 years) and those on SSRIs face highest risk.
When to Adjust Dosing
If blood pressure remains uncontrolled 4 weeks after conversion:
- First step: Increase chlorthalidone from 12.5 mg to 25 mg (if started at lower dose) 1
- Second step: Add second antihypertensive from different class rather than exceeding chlorthalidone 25 mg daily 6
- Avoid: Chlorthalidone doses >25 mg provide minimal additional blood pressure reduction but substantially increase metabolic adverse effects 3
Special Populations
Resistant hypertension: The 2025 AHA/ACC guidelines explicitly recommend replacing other thiazides with chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg as preferred agents 6. This conversion is appropriate and evidence-based.
CKD Stage 4 or greater (eGFR <30): Both chlorthalidone and loop diuretics are preferred over indapamide 6. The conversion remains appropriate.
Heart failure: Chlorthalidone starting dose should be 12.5 mg with careful volume status monitoring 1.